Moreover, Choe et al. reported that the anti-fibrotic effect of thalidomide on pulmonary fibrosis might be related to its inhibition of TGF-β1-induced activation of the ERK1/2 signaling pathway14. The gene discussed is MAPK3; the disease is pulmonary fibrosis.